BOSTON, June 18, 2025--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of intractable neurological diseases, announced today ...

Atalanta have sent an opening offer exceeding €17m for Kamaldeen Sulemana and are working to finalise the deal despite Southampton‘s request of €20m. Atalanta have made their opening offer ...

Serie A side Atalanta are interested in Southampton’s Kamaldeen Sulemana and progress is being made for a move. Alfredo Pedulla has reported that La Dea manager Ivan Juric has indicated the name ...

Doug Pagán joins as Chief Financial Officer & Chief Operating Officer, bringing deep financial, business strategy and RNAi expertise Atalanta Therapeutics, a biotechnology company pioneering RNA ...

Like Calhanoglu, Ederson is also under contract for another two years, with a deal running until the summer of 2027 with Atalanta. La Dea, like Inter and Calhanoglu, also know that Ederson has ...

Atalanta have identified Samuele Ricci as the ideal replacement if Ederson is sold for €60m this summer, despite there also being interest from Milan for the Torino midfielder. The Italy ...

Galapagos’ innovative decentralized cell therapy manufacturing platform has the potential for the administration of fresh, fit, stem-like early memory cells with a median vein-to-vein time of seven ...

epa11677903 Atalanta's Jose Ederson looks on during the UEFA Champions League soccer match between Atalanta BC and Celtic FC at the Bergamo Stadium in Bergamo, Italy, 23 October 2024. EPA-EFE ...

Reports in Italy claim that Massimiliano Allergi’s stance on Italy international Samuele Ricci hands an advantage to Atalanta in the race for his signature. Milan have been considering a move ...

Southampton winger Kamaldeen Sulemana could be reunited with former Saints boss Ivan Juric at Atalanta with the Italian Serie A side interested in signing the 23-year-old Ghana international this ...

Mechelen, Belgium; June 18, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today presented new data from the ongoing ATALANTA-1 Phase 1/2 study of its investigational CD19 CAR T-cell ...

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate ...